Increasing Vaccine Uptake in Underresourced Public Housing Areas

Community Partnered Intervention to Increase COVID-19 Vaccine Uptake in Low Income Underresourced African Americans and Latinx Public Housing Residents

This proposal seeks to enhance uptake and completion of COVID-19 vaccination among African American and Latinx public housing residents in South Los Angeles. Given the multiple disparities experienced by public housing residents, the investigators will utilize a theoretically-based, multidisciplinary and culturally tailored intervention to provide education at multiple levels and implement innovate strategies to engage this population in the uptake of COVID-19 vaccination.

Study Overview

• Status: Completed
• Conditions: Coronavirus; Vaccine Refusal
• Intervention / Treatment: Behavioral: Increasing Willingness and Uptake of COVID-19 Vaccination

Detailed Description

One particular group, African American and Latinx public housing residents, are facing adverse effects related to worsening social determinants and health disparities. Utilizing a community-driven approach, the overall objective of this proposed study is to increase COVID-19 vaccine uptake and completion the impact of COVID-19 among African American and Latinx public housing residents. Guided by the Community Based Participatory Model, the Information, Motivation, and Behavioral Skills (IMB) and the Transtheoretical Model will be utilized to carry out this intervention. Through this innovative program, we will establish Academic-Community Team for Improving Vaccine Acceptability and Targeted Engagement (ACTIVATE) program, which will develop leadership triads of public housing resident leaders, nurse practitioner students, and public health students to carry out this multilevel intervention.

• Study Type: Interventional
• Enrollment (Actual): 462
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90059
      • Charles R. Drew University of Medicine & Science

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Aim 2:

Inclusion Criteria:

• identify as Latinx or African American
• age 18 or older
• reside in one of the six collaborating public housing area
• Speak either English or Spanish

Exclusion Criteria:

• Not a resident at one of the collaborating public housing areas
• Does not self-identify as African American or Latinx
• Age 17 and younger
• Unable to speak either English or Spanish

Aim 3:

Inclusion Criteria:

• identify as Latinx or African American
• age 18 or older
• reside in one of the six collaborating public housing area
• Speak either English or Spanish
• Report vaccine hesitancy

Exclusion Criteria:

• Not a resident at one of the collaborating public housing areas
• Does not self-identify as African American or Latinx
• Age 17 and younger
• Unable to speak either English or Spanish
• Received all recommended vaccines for COVID-19
• No reporting of vaccine hesitancy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Increasing Uptake of COVID-19 Vaccination; This is a pre-experimental "one group pretest-posttest" design to increase COVID-19 vaccine uptake and completion among African American and Latinx public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our ACTIVATE triad leaders and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention.

Behavioral: Increasing Willingness and Uptake of COVID-19 Vaccination; Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce COVID-19 vaccine hesitancy and increase willingness and uptake in COVID-19 vaccination.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report	1. By comparison of pre-, post- intervention, and 9- and 18-months follow-up data, we anticipate the following compared to baseline: a 40% change in completion of COVID-19 vaccination series	Intervention: 4 months; Follow-up Point: 3 months post-intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19 vaccine Using the NIH Toolbox Surveys on COVID-19	1. By comparison of pre-, post- intervention, and 3-months follow-up data, we anticipate the following compared to baseline: a 40% change in hesitancy toward COVID-19 vaccination.	Intervention: 4 months; Follow-up Point: 3 months post-intervention
Percentage of Participants Achieving Increased Level of Behavior Change toward COVID-19 Vaccination Using the NIH Toolbox Surveys on COVID-19	2. By comparison of pre-, post- intervention, and 3-months follow-up data, we anticipate the following compared to baseline: a 40% change in their behavior stage of change toward COVID-19 vaccination	Intervention: 4 months; Follow-up Point: 3 months post-intervention

Collaborators and Investigators

• Sponsor: Charles Drew University of Medicine and Science
• Investigators: Principal Investigator: Sharon Cobb, Charles R. Drew University of Medicine & Science

Study record dates

Study Major Dates

• Study Start (Actual): September 11, 2021
• Primary Completion (Actual): November 30, 2023
• Study Completion (Actual): April 1, 2024

Study Registration Dates

• First Submitted: February 27, 2021
• First Submitted That Met QC Criteria: February 27, 2021
• First Posted (Actual): March 3, 2021

Study Record Updates

• Last Update Posted (Actual): April 24, 2024
• Last Update Submitted That Met QC Criteria: April 23, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Coronavirus Infections
• Other Study ID Numbers: vaccinehousing

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No